Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment

Oncologist

Volumn 8, Issue 1, 2003, Pages 35-44

  Haddad, Robert ^a,b   Tishler, Roy B ^c   Norris, Charles M ^d   Mahadevan, Anand ^c   Busse, Paul ^c   Wirth, Lori ^a   Goguen, Laura A ^d   Sullivan, Christopher A ^d   Costello, Rosemary ^b   Case, Mary Ann ^b   Posner, Marshall R ^a,b  

^a Department of Adult Oncology ^*  (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chemoradiotherapy; Head and neck cancer; Sequential chemoradiotherapy

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; TAXANE DERIVATIVE;

CANCER RECURRENCE; CANCER SURVIVAL; DRUG MECHANISM; HEAD AND NECK CANCER; HUMAN; META ANALYSIS; MULTIMODALITY CANCER THERAPY; NASOPHARYNX CANCER; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR CELL DESTRUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; PACLITAXEL; PROGNOSIS; RADIOTHERAPY, ADJUVANT; TAXOIDS;

EID: 0345074111     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.8-1-35     Document Type: Review

References (53)

1. Posner MR, Colevas AD, Tishler RB. The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. Semin Oncol 2000;27(suppl 8):13-24.
2. Forastiere A, Koch W, Trotti A et al. Head and neck cancer. N Engl J Med 2001;345:1890-1900.
3. Lefebvre JL, Chevalier D, Luboinski B et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 1996;88:890-898.
4. Domenge C, Hill C, Lefebvre JL et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Étude des Tumeurs de la Tête et du Cou (GETTEC). Br J Cancer 2000;83:1594-1598.
5. Paccagnella A, Orlando A, Marchiori C et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994;86:265-272.
6. Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685-1690.
7. Pignon JP, Bourhis J, Domenge C et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell cancer: three meta-analyses of updated individual data. Lancet 2000;355:949-955.
8. Harari PM. Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice? J Clin Oncol 1997;15:2050-2055.
9. Monnerat C, Faivre S, Temam S et al. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol 2002;13:995-1006.
10. Dunphy FR, Dunleavy TL, Harrison BR et al. Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 and 1999. Cancer 2001;91:940-948.
11. Shin DM, Glisson BS,Khuri FR et al. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 2002;95:322-330.
12. De Andres L, Brunet J, Lopez-Pousa A et al. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol 1995;13:1493-1500.
13. Forastiere AA, Metch B, Schuller DE et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245-1251.
14. Colevas AD, Busse PM, Norris CM et al. Induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol 1998;16:1331-1339.
15. Colevas AD, Norris CM, Tishler RB et al. A phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 1999;17:3503-3511.
16. Colevas AD, Norris CM, Tishler RB et al. Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). Am J Clin Oncol 2002;25:153-159.
17. Posner M, Glisson B, Frenette G et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2001;19:1096-1104.
18. Janinis J, Papadakou M, Panagos G et al. Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol 2001;24:227-231.
19. Devlin P, Kazakin J, Adak S, et al. Phase II trial of PFL-induction chemotherapy and local treatment for HNSCC: 10 year follow-up. Proc Am Soc Clin Oncol 2002;21:913a.
20. Clark JR, Busse PM, Norris Jr CM et al. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results. J Clin Oncol 1997;15:3100-3110.
21. Haddad R, Colevas AD, Tishler R et al. Docetaxel, cisplatin and 5-fluorouracil based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: The Dana-Farber Cancer Institute experience. Cancer 2002;97:412-418.
22. WAF1/CIP1. Br J Cancer 1996;27(suppl):S82-S85.
23. Tishler RB, Schiff PB, Geard CR et al. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992;22:613-617.
24. Milas L, Saito Y, Hunter N et al. Therapeutic potential of paclitaxel-radiation treatment of a murine ovarian carcinoma. Radiother Oncol 1996;40:163-170.
25. Tishler RB, Busse PM, Norris Jr CM et al. An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. Int J Radiat Oncol Biol Phys 1999;43:1001-1008.
26. Tishler RB, Norris Jr CM, Colevas AD et al. A phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer 2002;95:1472-1481.
27. Douple EB, Richmond RC, O'Hara JA et al. Carboplatin as a potentiator of radiation therapy. Cancer Treat Rev 1985;12(suppl):111-124.
28. Jeremic B, Shibamoto Y, Stanisavljevic B et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol 1997;43:29-37.
29. Calais G, Alfonsi M, Bardet E et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081-2086.
30. Brizel DM, Albers ME, Fisher SR et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-1804.
31. Smid L, Lesnicar H, Zakotnik B et al. Radiotherapy, combined with simultaneous chemotherapy with mitomycin C and bleomycin for inoperable head and neck cancer - preliminary report. Int J Radiat Oncol Biol Phys 1995;32:769-775.
32. Adelstein DJ, Lavertu P, Saxton JP et al. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 2000;88:876-883.
33. Al-Sarraf M, LeBlanc M, Giri PG et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-1317.
34. Staar S, Rudat V, Stuetzer H et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy - results of a multicentric randomized German trial in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 2001;50:1161-1171.
35. Denis F, Alfonsi M, Bardet E et al. Late toxicity results of randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma (GORTEC 94-01) [Abstract]. Proceedings of the 43rd Annual ASTRO Meeting 2001;39.
36. Adelstein D, Adams G, Li Y et al. A phase III comparison of standard radiation therapy (RT) versus RT plus concurrent cisplatin (DDP) versus split-course RT plus concurrent DDP and 5-fluorouracil (5-FU) in patients with unresectable squamous cell head and neck cancer (SCHNC): an Intergroup study. Proc Am Soc Clin Oncol 2000;19:411a.
37. Jacobs MC, Eisenberger M, Oh MC et al. Carboplatin (CBDCA) and radiotherapy for stage IV carcinoma of the head and neck: a phase I-II study. Int J Radiat Oncol Biol Phys 1989;17:361-363.
38. Jeremic B, Shibamoto Y, Milicic SB et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000;18:1458-1464.
39. Suntharalingam M, Haas ML, Conley BA et al. The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2000;47:49-56.
40. Garden AS, Pajak TF, Vokes E et al. Preliminary results of RTOG 9703 - a phase II randomized trial of concurrent radiation (RT) and chemotherapy for advanced squamous cell carcinomas (SCC) of the head and neck. Proc Am Soc Clin Oncol 2001;20:223a.
41. Kies MS, Haraf DJ, Rosen F et al. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol 2001;19:1961-1969.
42. Vokes EE, Kies MS, Haraf DJ et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 2000;18:1652-1661.
43. Fu KK, Pajak TF, Trotti A et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.
44. Forastiere AA, Berkey B, Maor M et al. Phase III trial to preserve the larynx: induction chemotherapy and radiotherapy versus concomitant chemoradiotherapy versus radiotherapy alone, Intergroup Trial R91-11. Proc Am Soc Clin Oncol 2001;20:2a.
45. Spaulding MB, Fischer SG, Wolf GT. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. J Clin Oncol 1994;12:1592-1599.
46. Vokes EE, Weichselbaum RR, Mick R et al. Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. J Natl Cancer Inst 1992;84:877-882.
47. Vokes EE, Kies M, Haraf DJ et al. Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease. J Clin Oncol 1995;13:876-883.
48. Posner M. Sequential chemotherapy for the curative treatment of squamous cell cancer of the head and neck: a new paradigm. Oncol Spectr 2001;2:193-202.
49. Vokes EE, Rosen FR, Kies MS et al. Weekly carboplatin and paclitaxel followed by concomitant T-FHX chemoradiotherapy for advanced head and neck cancer: a potentially successful strategy. Proc Am Soc Clin Oncol 2002;21:230a.
50. Machtay M, Rosenthal DI, Hershock D et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania phase II trial. J Clin Oncol 2002;20:3964-3971.
51. Gray J, Meluch A, Greco F 3rd et al. Induction paclitaxel/carboplatin/5-FU followed by concurrent radiotherapy and weekly paclitaxel/carboplatin for patients with locally advanced head and neck cancer (HNC): a Minnie Pearl Cancer Research Network trial. Proc Am Soc Clin Oncol 2002;20:226a.
52. Worden FP, Urba SG, Bradford C et al. Induction chemotherapy to select for concomitant chemoradiation as organ preservation for patients with advanced squamous carcinoma of the oral cavity/oropharynx (OC/OP). Proc Am Soc Clin Oncol 2002;21:239a.
53. Clark JR, Fallon BG, Dreyfuss AI et al. Chemotherapeutic strategies in the multidisciplinary treatment of head and neck cancer. Semin Oncol 1988;15(suppl):35-44.